Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07604571 · ClinicalTrials.gov registry record · Phase 1
Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 194
- Enrollment target
NCT07604571 is a Phase 1 study that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 194 participants.
The verdict
NCT07604571, a Phase 1 study, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 194 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability and preliminary activity of IEV407 as a single agent and in combination with endocrine therapy (fulvestrant or letrozole) in patients with advanced hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-negative) breast cancer.
Interventions
- DRUG Letrozole
- DRUG Fulvestrant
- DRUG IEV407
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 194 participants |
| Start Date | 2026-05-28 |
| Est. Completion | 2032-06-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07604571
The ClinicalTrials.gov registry entry for NCT07604571 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 194 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Letrozole is the first listed.
NCT07604571 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07604571 about?
NCT07604571 is a clinical study titled "Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer". The purpose of this study is to evaluate the safety, tolerability and preliminary activity of IEV407 as a single agent and in combination with endocrine therapy (fulvestrant or letrozole) in patients with advanced hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HE...
What is the current status of trial NCT07604571?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 194 participants. The study started on 2026-05-28. Estimated completion is 2032-06-08.
What interventions are being tested in trial NCT07604571?
The interventions under investigation include: Letrozole (DRUG), Fulvestrant (DRUG), IEV407 (DRUG).
Who is sponsoring clinical trial NCT07604571?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.